What is Mimetas?
MIMETAS is at the forefront of advanced drug discovery, pioneering human tissue models that precisely replicate human physiology. Their proprietary OrganoPlate platform, coupled with organoids and comprehensive CRO services, is designed to accelerate research in critical areas such as oncology, immunology, and metabolic diseases. By providing deep insights into drug efficacy and safety, MIMETAS empowers pharmaceutical innovation, aiming to reduce reliance on animal testing while ensuring robust and reproducible scientific outcomes.
How much funding has Mimetas raised?
Mimetas has raised a total of $6.8M across 2 funding rounds:
Unspecified
$1.6M
Unspecified
$5.2M
Unspecified (2014): $1.6M, investors not publicly disclosed
Unspecified (2014): $5.2M led by Participatiemaatschappij Oost Nederland NV and Zeeuws InvesterinsFonds
Key Investors in Mimetas
Participatiemaatschappij Oost Nederland NV
PPM Oost is the public venture capital arm for the East Netherlands region, focusing on promising companies that lead regional economic development in Gelderland and Overijssel, particularly within key Dutch technology sectors.
Zeeuws InvesterinsFonds
Zeeuws InvesteringsFonds supports the growth of businesses and entrepreneurs in the Zeeland region, providing strategic capital and operational support to promising ventures.
What's next for Mimetas?
The substantial enterprise-level capital infusion, highlighted by the recent strategic investment, positions Mimetas for accelerated scaling and further innovation in its organ-on-a-chip technology. This backing is expected to fuel advancements in their platform development, expand their CRO service offerings, and deepen their market penetration within the pharmaceutical and biotechnology sectors. The company is poised to solidify its role in reducing preclinical drug development timelines and costs.
See full Mimetas company page
